Page URL:

Prostate cancer gene study should change treatment approach, say scientists

15 April 2013
Appeared in BioNews 700

Prostate cancer patients who have inherited a well-known gene mutation are more likely to develop an aggressive form of the disease, a study shows.

It was already known that men carrying the BRCA2 mutation were at greater risk of prostate cancer. But research published in the Journal of Clinical Oncology shows that the cancers spread faster and are more often fatal in these patients.

As it can be difficult for doctors to determine whether newly diagnosed prostate cancer will be life-threatening, many patients are currently put under 'active surveillance' rather than put forward for immediate treatment.

But senior author Ros Eeles, professor of oncogenetics at the Institute of Cancer Research (ICR) says that NHS guidance should change to take into account the study's findings.

'It is clear from our study that prostate cancers linked to inheritance of the BRCA2 cancer gene are more deadly than other types', she said. 'It must make sense to start offering affected men immediate surgery or radiotherapy, even for early-stage cases that would otherwise be classified as low-risk'.

Around one percent of prostate cancer patients will have the BRCA2 mutation. Professor Eeles admits that without clinical trials it is impossible to be sure that this group of men would benefit from earlier treatment. All the same, she says, 'the hope is that our study will ultimately save lives by directing treatment at those who most need it'.

In the study researchers examined the medical records of 61 prostate cancer patients carrying the BRCA2 mutation as well as 18 patients with the related BRCA1 mutation and 1,940 non-carriers.

They found that when they received the diagnosis, men with either mutation were significantly more likely to have advanced stage cancer, or cancer that had already spread, than other patients. Crucially, patients with BRCA2 mutations were significantly less likely to survive the cancer, living an average of six and a half years after diagnosis compared with nearly 13 years for non-carriers. BRCA1 carriers also had reduced survival time, but this was not statistically significant.

Professor Alan Ashworth, chief executive of the ICR, said that the study illustrated how 'knowledge of cancer genetics is now increasingly shaping the way we treat the disease, by allowing us to offer more intensive treatment, or even different drugs altogether, for people who have inherited cancer genes'.

The study was a UK Clinical Research Network portfolio study, funded by the Ronald and Rita McAulay Foundation and Cancer Research UK.

'Aggressive' prostate cancer gene find
BBC News |  9 April 2013
Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
Journal of Clinical Oncology |  8 April 2013
Scientists find that prostate cancer patients with BRCA2 mutations require urgent treatment
The Institute of Cancer Research (press release) |  8 April 2013
15 September 2014 - by Dr Anna Cauldwell 
Twenty-three genetic variants associated with increased risk of prostate cancer have been identified in a new study, bringing the total number of susceptibility variants for the disease to 100...
14 April 2014 - by Simon Hazelwood-Smith 
A genetic test has been developed to predict the likelihood of prostate cancer returning after treatment. The test looks for 'genetic signatures' often found in recurring cancers...
24 February 2014 - by Julianna Photopoulos 
Genetic screening could help identify men who are most likely to develop an aggressive form of prostate cancer, a study shows...
16 September 2013 - by Daniel Riddell 
Advances in DNA sequencing mean that high-throughput, routine genetic testing of people with cancer is now a realistic possibility...
12 August 2013 - by Dr Sophie Pryor 
A new diagnostic test that detects whether breast cancer has spread has been recommended for use in NHS practice by the National Institute for Health and Care Excellence (NICE)...
8 April 2013 - by Siobhan Chan 
The largest ever study into cancer genes has identified more than 80 genetic markers for breast, prostate and ovarian cancer....
16 January 2012 - by Dr Linda Wijlaars 
A rare gene variant that could increase the risk of prostate cancer has been identified by researchers in the USA. Although the variant accounts for only a small fraction of all prostate cancers, the study found it was more common in men with an inherited form of the cancer and in those who are diagnosed before the age of 55...
1 August 2011 - by Dr Charlotte Maden 
Two new initiatives have been launched by Cancer Research UK, aiming to increase the understanding of prostate and oesophageal cancers which will speed up the development of personalised treatments for patients....
28 September 2009 - by Dr Charlotte Maden 
Four genetic studies into prostate cancer have uncovered new genetic variations associated with the disease. The information may be used to provide a more reliable indication of the risk a man has of developing prostate cancer....
18 February 2008 - by Stuart Scott 
Three studies, published in the journal Nature Genetics, have uncovered ten genes that affect a man's risk of developing prostate cancer. The researchers hope that the discoveries will form the basis of a test that will predict men's chances of developing prostate cancer, as well as providing...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.